三生製藥(01530.HK)附屬與瑞士生物製藥商合作開發新型腫瘤免疫多特異性抗體
三生製藥(01530.HK)公布,集團附屬三生國健與瑞士蘇黎世區的生物製藥公司Numab Therapeutics合作開發一系列腫瘤免疫新型多特異性抗體。三生國健將基於Numab的技術平台開發和商業化一系列用於癌症治療的新型多特異性抗體。
根據協議,三生國健有權在Numab研發平台的三個多特異性抗體項目中選取多達五種抗體分子,並擁有所選抗體分子在大中華區(包括中國大陸、香港、澳門和台灣)的開發及商業化專有許可權,其他區域的獨家商業權利由Numab保留。同時,三生國健已經在Numab的B輪融資中投資了1,500萬瑞士法郎(約1,520萬美元)。
集團指,Numab的獨家MATCHTM技術已經造就了一個強大的多特異性抗體候選藥物管線,其主導項目ND021是一種抗-4-1BB/PD-L1/HSA三特異性抗體,將在明年進入臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.